Complex genetic encoding of the hepatitis B virus on-drug persistence
Authors:
Open Access
- 23 September 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-13
Abstract
Tenofovir disoproxil fumarate (TDF) is one of the nucleotide analogs capable of inhibiting the reverse transcriptase (RT) activity of HIV and hepatitis B virus (HBV). There is no known HBV resistance to TDF. However, detectable variation in duration of HBV persistence in patients on TDF therapy suggests the existence of genetic mechanisms of on-drug persistence that reduce TDF efficacy for some HBV strains without affording actual resistance. Here, the whole genome of intra-host HBV variants (N = 1,288) was sequenced from patients with rapid (RR, N = 5) and slow response (SR, N = 5) to TDF. Association of HBV genomic and protein polymorphic sites to RR and SR was assessed using phylogenetic analysis and Bayesian network methods. We show that, in difference to resistance to nucleotide analogs, which is mainly associated with few specific mutations in RT, the HBV on-TDF persistence is defined by genetic variations across the entire HBV genome. Analysis of the inferred 3D-structures indicates no difference in affinity of TDF binding by RT encoded by intra-host HBV variants that rapidly decline or persist in presence of TDF. This finding suggests that effectiveness of TDF recognition and binding does not contribute significantly to on-drug persistence. Differences in patterns of genetic associations to TDF response between HBV genotypes B and C and lack of a single pattern of mutations among intra-host variants sensitive to TDF indicate a complex genetic encoding of the trait. We hypothesize that there are many genetic mechanisms of on-drug persistence, which are differentially available to HBV strains. These pervasive mechanisms are insufficient to prevent viral inhibition completely but may contribute significantly to robustness of actual resistance. On-drug persistence may reduce the overall effectiveness of therapy and should be considered for development of more potent drugs.Keywords
This publication has 55 references indexed in Scilit:
- A Polymorphism at Position 400 in the Connection Subdomain of HIV-1 Reverse Transcriptase Affects Sensitivity to NNRTIs and RNaseH ActivityPLOS ONE, 2013
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Convergence and coevolution of Hepatitis B virus drug resistanceNature Communications, 2012
- Evaluation of Intra-Host Variants of the Entire Hepatitis B Virus GenomePLOS ONE, 2011
- Long‐term outcome of primary non‐responders to tenofovir therapy in HIV/HBV‐co‐infected patients: impact of HBV genotype GLiver International, 2011
- Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected PatientsISRN Gastroenterology, 2011
- Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptaseVirus Research, 2008
- Hepatitis B virus genetic variability and evolutionVirus Research, 2007
- HBV drug resistance: Mechanisms, detection and interpretationJournal of Hepatology, 2006
- On Information and SufficiencyThe Annals of Mathematical Statistics, 1951